Damon Runyon Cancer Research Foundation Announces 2018 Fellows

Damon Runyon Cancer Research Foundation Announces 2018 Fellows

The Damon Runyon Cancer Research Foundation in New York City has announced fellowships totaling more than $4.2 million to a new cohort of postdoctoral scientists conducting basic and translational research in the laboratories of leading senior investigators. 

Eighteen early-career physician-scientists were awarded fellowships of $231,000 each over four years to pursue innovative research under the direct supervision of a sponsoring scientist on the causes, mechanisms, prevention of, and/or therapies for cancer.

This year's recipients include Matthew Bakalar (Broad Institute, Cambridge, Massachusetts), who is developing new methods to identify the millions of interactions between T-cell receptors and foreign antigens that trigger an immune response; Allison Didychu (University of California, Berkeley), who is investigating the mechanism by which the Kaposi's sarcoma herpesvirus co-opts the cellular host machinery to produce its own gene products in a manner distinct from other viruses and host cells; Eric E. Gardner, (Weill Cornell Medicine, New York City), who is using both human and mouse models to identify therapeutic approaches that may treat, prevent, or reverse acquired resistance to targeted therapies in lung cancer; Whitney Johnson (Dana-Farber Cancer Institute, Boston, Massachusetts), who is studying how genome rearrangements occur in cancer using artificial pancreatic cancer organoids — clusters of cells that act as a model system; and Xiaoyu Zhang (Scripps Research Institute, La Jolla, California), who is developing small molecules that promote targeted protein degradation in human cancers.

For a complete list of the most recent cohort of Runyon Fellows, see the Damon Runyon Cancer Research Foundation website.